GW Specialists Out there to Focus on Public Well being Penalties of the Current Court docket Rulings on Mifepristone

GW Specialists Out there to Focus on Public Well being Penalties of the Current Court docket Rulings on Mifepristone

Resolution Upends Drug Approval Course of and Continues to Put Entry to this Treatment at Threat

WASHINGTON (April 13, 2023)—Yesterday a federal appeals courtroom blocked a ruling by a Texas decide to droop the Meals and Drug Administration’s approval of the abortion medicine known as mifepristone. The ruling preserves entry to this medicine for now however public well being consultants say entry to this important well being care service continues to be in danger. The appeals courtroom additionally declined to dam one other a part of the Texas ruling which invalidated the FDA approval course of for this drug. If allowed to face, consultants say the Texas ruling might upend the FDA technique of drug approval.

The George Washington College has consultants out there to touch upon the FDA approval course of and the general public well being penalties of this courtroom battle over mifepristone. To schedule an interview contact Kathy Fackelmann at [email protected] or GW Media at [email protected].

Julia Strasser is a analysis professor of well being coverage and administration in addition to Director of the Jacobs Institute of Ladies’s Well being on the GW Milken Institute Faculty of Public Well being. She is an knowledgeable on reproductive well being and the abortion supplier workforce. She is accessible to touch upon the affect of revoking FDA’s approval of mifepristone on ladies’s well being.

Elizabeth Borkowski is a senior analysis scientist in well being coverage and administration on the GW Milken Institute Faculty of Public Well being. Her areas of experience embody reproductive well being and U.S. healthcare coverage affecting ladies’s well being. She is accessible to touch upon the science and security of mifepristone in addition to the FDA approval course of.

Borkowski and Strasser are the authors of a latest op-ed on this matter in Scientific American that claims:

“When federal Choose Matthew Kacsmaryk suspended the Meals and Drug Administration (FDA) approval of the drug mifepristone on April 7, he considerably jeopardized entry to abortion. Along with dealing a direct blow to accessing an important and time-sensitive well being care service, this choice additionally upended a drug approval system that for many years has been primarily based on scientific proof and knowledgeable medical opinions. Kacsmaryk overshadowed a trusted system with the specter of a drug provide formed by judicial fiat.”

-GW-

#Specialists #Focus on #Public #Well being #Penalties #Court docket #Rulings #Mifepristone, 1681399478

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top